These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14716027)

  • 1. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
    Voutsadakis IA
    Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
    Heinrich MC
    Mini Rev Med Chem; 2004 Mar; 4(3):255-71. PubMed ID: 15032673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
    Sternberg DW; Licht JD
    Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
    Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
    Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
    Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
    Reilly JT
    Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
    Spiekermann K; Hiddemann W; Schnittger S
    Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
    [No Abstract]   [Full Text] [Related]  

  • 10. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
    Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
    Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule FLT3 tyrosine kinase inhibitors.
    Levis M; Small D
    Curr Pharm Des; 2004; 10(11):1183-93. PubMed ID: 15078134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
    Spiekermann K; Bagrintseva K; Schoch C; Haferlach T; Hiddemann W; Schnittger S
    Blood; 2002 Nov; 100(9):3423-5. PubMed ID: 12384447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 Inhibitors in the Treatment of AML.
    Gilliland DG
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
    [No Abstract]   [Full Text] [Related]  

  • 16. Flt3 receptor tyrosine kinase as a drug target in leukemia.
    Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
    Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3: ITDoes matter in leukemia.
    Levis M; Small D
    Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 tyrosine kinase as a target in acute leukemias.
    Griffin JD
    Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of FLT3 mutations in the therapy of acute myeloid leukemia.
    Mattison RJ; Ostler KR; Locke FL; Godley LA
    Rev Recent Clin Trials; 2007 May; 2(2):135-41. PubMed ID: 18473998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
    Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.